Document is current

Article History

Received: 9 February 2023

Accepted: 17 March 2023

First Online: 2 May 2023

Declarations

:

: S.M. received research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, GSK/Tesaro, and Teva. F.T. declares research support, advisory board, honoraria and travel expenses from AstraZeneca, Eisai, Clovis, ImmunoGen, Medac, MSD, PharmaMar, Roche, and GSK/Tesaro,. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

: Approval by the Ethics Committee of the Ludwig-Maximilian-University, Munich, Germany was obtained (approval number 227-09 and 18-392). The analyzed tumor samples were formerly utilized for pathological diagnostics and then archived by the Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. The patient’s personal data was entirely anonymized and investigators were blinded during the analysis.

: The studies involving human participants were reviewed and approved by Ludwig-Maximilian-University, Munich, Germany. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

: Not applicable.